The Only Patented, FDA-Cleared DSEK Inserter on the Market

The NCI® Spatula is engineered to help you achieve better outcomes in DSEK procedures — by eliminating the risk of viscoelastic residue at the graft-host interface, a known contributor to graft failure and endothelial cell loss.

Clinically Proven Performance

A study conducted at Devers Eye Institute demonstrated that the NCI® Spatula delivers statistically significant reductions in endothelial cell loss (ECL) compared to standard forceps insertion:

"For the whole group of 10 grafts, mean ECL was 15.58% (95% CI: 13.78–17.38). This represents a mean difference of 2.4% less than the 18% ECL reported from tissue insertion using Charlie forceps through a 5mm wound (Terry 2009). This difference is statistically significant (t=−3.041, two-tailed p=0.014). The 95% confidence interval for the true difference is −4.22 to −0.62."

• No viscoelastics of any kind were used during NCI® graft insertion
• Performance is further optimized with thinner donor tissue

Data provided by Devers Eye Institute. Devers Eye Institute has no financial interest in Fischer Surgical Inc. or the NCI® Spatula.

Surgeon Testimonial

"I used the NCI Spatula on a DSAEK last Thursday and I am so impressed at how gently I was able to insert the tissue into the anterior chamber. It worked great with seemingly no trauma to the tissue at all!"

David B. Warner, MD
Assistant Professor of Ophthalmology
Director of Cornea & External Disease Service
Medical Director, Arkansas Lions Eye Bank
University of Arkansas for Medical Sciences
Little Rock, AR 72205
(501) 686-5150